Petignat P, Usel M, Gauthier P, Popowski Y, Pelte M F, Bouchardy C, Verkooijen H M
Gynecologic Oncology Service, Centre hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, Quebec, Canada.
Eur J Gynaecol Oncol. 2008;29(1):57-60.
Our aim was to compare the survival between patients with clear cell carcinoma (CC) and patients with endometrioid carcinoma (EC).
Through the population-based Geneva Cancer Registry, we identified 1,380 resident women diagnosed with uterine cancer between 1970 and 2000. We excluded those with papillary serous endometrial carcinoma and uterine sarcomas. We categorized patients as CC (n = 32, 2.8%) or EC (n = 1,145, 97.2%). Uterine cancer-specific survival rates were calculated by Kaplan-Meier analysis. We used Cox proportional hazards analysis to compare uterine cancer mortality risks between groups, and adjusted these risks for other prognostic factors.
CC patients presented with a more advanced stage at diagnosis than EC patients (p = 0.002). Compared to women with EC, women with CC had a significantly greater risk of dying from their disease (hazard ratio [HR] 2.9, 95% confidence interval (95% CI) 1.7-4.9). After adjustment for age, stage and adjuvant chemotherapy, the risk of dying from uterine cancer was still significantly higher for CC patients (HR 2.0, 95% CI 1.2-3.4). By univariate analysis, the risk of dying of endometrial cancer was not significantly higher in CC patients than in patients with poorly-differentiated EC (HR 1.3, 95% CI 0.7-2.3).
This population-based investigation shows that patients with CC have a poorer outcome than those with EC. Studies to determine the role of adjuvant treatment in CC patients are needed.
我们的目的是比较透明细胞癌(CC)患者和子宫内膜样癌(EC)患者的生存率。
通过基于人群的日内瓦癌症登记处,我们确定了1970年至2000年间被诊断为子宫癌的1380名常住女性。我们排除了那些患有乳头状浆液性子宫内膜癌和子宫肉瘤的患者。我们将患者分为CC组(n = 32,2.8%)或EC组(n = 1145,97.2%)。采用Kaplan-Meier分析计算子宫癌特异性生存率。我们使用Cox比例风险分析比较两组之间的子宫癌死亡风险,并针对其他预后因素调整这些风险。
CC患者在诊断时的分期比EC患者更晚(p = 0.002)。与EC女性相比,CC女性死于疾病的风险显著更高(风险比[HR] 2.9,95%置信区间(95%CI)1.7 - 4.9)。在调整年龄、分期和辅助化疗后,CC患者死于子宫癌的风险仍然显著更高(HR 2.0,95%CI 1.2 - 3.4)。通过单因素分析,CC患者死于子宫内膜癌的风险并不比低分化EC患者显著更高(HR 1.3,95%CI 0.7 - 2.3)。
这项基于人群的调查表明,CC患者的预后比EC患者更差。需要开展研究以确定辅助治疗在CC患者中的作用。